BRPI0514666A - antagonistas de receptor de endotelina a (eta) em combinação com inibidores de fosfodiestrase 5 (pdes) e usos destes - Google Patents
antagonistas de receptor de endotelina a (eta) em combinação com inibidores de fosfodiestrase 5 (pdes) e usos destesInfo
- Publication number
- BRPI0514666A BRPI0514666A BRPI0514666-6A BRPI0514666A BRPI0514666A BR PI0514666 A BRPI0514666 A BR PI0514666A BR PI0514666 A BRPI0514666 A BR PI0514666A BR PI0514666 A BRPI0514666 A BR PI0514666A
- Authority
- BR
- Brazil
- Prior art keywords
- combination
- pdes
- inhibitors
- receptor antagonists
- phosphodiestrase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Gynecology & Obstetrics (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
ANTAGONISTAS DE RECEPTOR DE ENDOTELINA A (ET~ A~) EM COMBINAçãO COM INIBIDORES DE FOSFODIESTERASE 5 (PDES) E USOS DESTES A presente invenção refere-se em geral às terapias de combinação compreendendo um antagonista de receptor de endotelina A (ET~ A~) e um inibidor de fosfodiesterase 5 (PDE5), composições farmacêuticas compreendendo o antagonista de ET~ A~ e inibidor de PDE5 e métodos de tratar vários distúrbios compreendendo administrar um antagonista de ET~ A~ e um inibidor de PDE5. Em particular, as terapias de combinação e composições farmacêuticas são úteis para o tratamento e/ou prevenção de distúrbios cardíacos como hipertensão arterial pulmonar (PAH).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60446204P | 2004-08-26 | 2004-08-26 | |
US11/211,099 US20060205733A1 (en) | 2004-08-26 | 2005-08-25 | Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof |
PCT/US2005/030342 WO2006026395A1 (en) | 2004-08-26 | 2005-08-26 | Endothelin a receptor (eta) antagonists in combination with phosphodiesterase 5 inhibitors (pde5) and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0514666A true BRPI0514666A (pt) | 2008-06-17 |
Family
ID=36000390
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0514666-6A BRPI0514666A (pt) | 2004-08-26 | 2005-08-26 | antagonistas de receptor de endotelina a (eta) em combinação com inibidores de fosfodiestrase 5 (pdes) e usos destes |
Country Status (12)
Country | Link |
---|---|
US (1) | US20060205733A1 (pt) |
EP (1) | EP1789051A4 (pt) |
JP (1) | JP2008510830A (pt) |
KR (1) | KR20070074552A (pt) |
AU (1) | AU2005280077A1 (pt) |
BR (1) | BRPI0514666A (pt) |
CA (1) | CA2578044A1 (pt) |
IL (1) | IL181513A0 (pt) |
MX (1) | MX2007002311A (pt) |
NO (1) | NO20071446L (pt) |
RU (1) | RU2007110933A (pt) |
WO (1) | WO2006026395A1 (pt) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8088918B2 (en) | 2004-08-11 | 2012-01-03 | Williamsburg Holdings Llc | Noncardiotoxic pharmaceutical compounds |
MX2007006069A (es) * | 2004-11-18 | 2007-07-11 | Schering Corp | Metodos para utilizar inhibidores de la fosfodiesterasa tipo v y para el tratamiento de insuficiencia cardiaca congestiva. |
DE102005016345A1 (de) * | 2005-04-09 | 2006-10-12 | Bayer Healthcare Ag | Neue Verwendung von 2-Phenyl-substituierten Imidazotriazinon-Derivaten |
MX2008000087A (es) * | 2005-06-23 | 2008-03-18 | Schering Corp | Formulaciones orales rapidamente absorbentes de inhibidores de la fosfodiesterasa 5. |
US20070196510A1 (en) * | 2006-02-17 | 2007-08-23 | Gerber Michael J | Method for treating resistant hypertension |
WO2007106467A2 (en) | 2006-03-13 | 2007-09-20 | Encysive Pharmaceuticals, Inc. | Polymorphs of n-(4-chloro-3-methyl-5-isoxazolyl)2-[2-methyl-4,5-(methylenedioxy) phenylacetyl]thiophene-3-sulfonamide, sodium salt |
KR20080104149A (ko) * | 2006-03-13 | 2008-12-01 | 엔싸이시브 파마슈티칼즈 인코퍼레이티드 | 확장기 심장 부전의 치료를 위한 방법 및 조성물 |
CA2644784A1 (en) * | 2006-03-13 | 2007-09-20 | Jinling Chen | Formulations of sitaxsentan sodium |
WO2007133796A2 (en) * | 2006-05-15 | 2007-11-22 | Encysive Pharmaceuticals, Inc. | Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist |
FR2902009B1 (fr) * | 2006-06-13 | 2012-12-07 | Bioprojet Soc Civ | Utilisation d'un inhibiteur de vasopeptidase pour le traitement de l'hypertension arterielle pulmonaire |
CA2655144A1 (en) * | 2006-06-15 | 2007-12-21 | Gilead Colorado, Inc. | Antihypertensive therapy method |
AR062501A1 (es) | 2006-08-29 | 2008-11-12 | Actelion Pharmaceuticals Ltd | Composiciones terapeuticas |
AU2007333115B2 (en) * | 2006-12-12 | 2013-01-10 | Gilead Sciences, Inc. | Composition for treating a pulmonary hypertension |
WO2008088727A2 (en) | 2007-01-12 | 2008-07-24 | Concert Pharmaceuticals, Inc. | Endothelin receptor antagonists |
US8080549B2 (en) * | 2007-01-12 | 2011-12-20 | Concert Pharmaceuticals, Inc. | Endothelin receptor antagonists |
EA019833B1 (ru) | 2007-01-22 | 2014-06-30 | ДЖиТиЭкс, ИНК. | Вещества, связывающие ядерные рецепторы |
US9623021B2 (en) * | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
US9604931B2 (en) | 2007-01-22 | 2017-03-28 | Gtx, Inc. | Nuclear receptor binding agents |
WO2008112241A1 (en) * | 2007-03-13 | 2008-09-18 | Encysive Pharmaceuticals, Inc. | Methods an compositions for treatment of an interstitial lung disease |
AU2013203192B2 (en) * | 2007-06-11 | 2015-12-24 | Edge Therapeutics Inc. | A drug delivery system for the prevention of cerebral vasospasm |
KR101554250B1 (ko) * | 2007-06-11 | 2015-09-18 | 알. 로치 맥도날드 | 뇌혈관 연축의 예방을 위한 약물 전달 시스템 |
US10092524B2 (en) | 2008-06-11 | 2018-10-09 | Edge Therapeutics, Inc. | Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage |
RU2010114029A (ru) * | 2007-09-11 | 2011-10-20 | Мондобайотек Лабораториз Аг (Li) | Астрессин и бета-эндорфин для применения в качестве терапевтических средств |
CN101891747B (zh) * | 2010-07-02 | 2012-04-25 | 张南 | 抑制5型磷酸二酯酶的化合物及制备方法 |
SI2637664T1 (sl) * | 2010-10-15 | 2017-07-31 | Gilead Sciences, Inc. | Sestavki in postopki zdravljenja pljučne hipertenzije |
KR20140052992A (ko) | 2011-04-05 | 2014-05-07 | 에쥐 세라피틱스, 인코포레이티드 | 뇌혈류에 영향을 미치는 뇌손상 후 결과를 개선시키기 위한 뇌실내 약물 전달 시스템 |
MX358151B (es) * | 2012-01-31 | 2018-08-07 | Eisai R&D Man Co Ltd | Derivado de sitaxentan. |
US9399019B2 (en) | 2012-05-09 | 2016-07-26 | Evonik Corporation | Polymorph compositions, methods of making, and uses thereof |
US20160015701A1 (en) * | 2013-03-08 | 2016-01-21 | Abbive Inc. | Methods of Treating Acute Kidney Injury |
WO2018081567A1 (en) * | 2016-10-27 | 2018-05-03 | Pulmokine, Inc. | Combination therapy for treating pulmonary hypertension |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5250534A (en) * | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US6451807B1 (en) * | 1999-04-30 | 2002-09-17 | Lilly Icos, Llc. | Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor |
NO20002097L (no) * | 1999-04-30 | 2001-10-26 | Lilly Icos Llc | Fremstillingsgjenstander |
JP2004525890A (ja) * | 2001-02-02 | 2004-08-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | ピラゾロ[4,3−d]ピリミジンおよびエンドセリンレセプターアンタゴニストまたはチエノピリミジンおよびエンドセリンレセプターアンタゴニストを含む医薬製剤 |
GB0214784D0 (en) * | 2002-06-26 | 2002-08-07 | Pfizer Ltd | Novel combination |
-
2005
- 2005-08-25 US US11/211,099 patent/US20060205733A1/en not_active Abandoned
- 2005-08-26 CA CA002578044A patent/CA2578044A1/en not_active Abandoned
- 2005-08-26 EP EP05792498A patent/EP1789051A4/en not_active Withdrawn
- 2005-08-26 WO PCT/US2005/030342 patent/WO2006026395A1/en active Application Filing
- 2005-08-26 MX MX2007002311A patent/MX2007002311A/es unknown
- 2005-08-26 KR KR1020077006248A patent/KR20070074552A/ko not_active Application Discontinuation
- 2005-08-26 JP JP2007530143A patent/JP2008510830A/ja active Pending
- 2005-08-26 RU RU2007110933/14A patent/RU2007110933A/ru not_active Application Discontinuation
- 2005-08-26 BR BRPI0514666-6A patent/BRPI0514666A/pt not_active IP Right Cessation
- 2005-08-26 AU AU2005280077A patent/AU2005280077A1/en not_active Abandoned
-
2007
- 2007-02-22 IL IL181513A patent/IL181513A0/en unknown
- 2007-03-16 NO NO20071446A patent/NO20071446L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2005280077A1 (en) | 2006-03-09 |
IL181513A0 (en) | 2007-07-04 |
EP1789051A4 (en) | 2009-10-21 |
MX2007002311A (es) | 2008-03-10 |
CA2578044A1 (en) | 2006-03-09 |
WO2006026395A1 (en) | 2006-03-09 |
KR20070074552A (ko) | 2007-07-12 |
EP1789051A1 (en) | 2007-05-30 |
JP2008510830A (ja) | 2008-04-10 |
NO20071446L (no) | 2007-03-26 |
RU2007110933A (ru) | 2008-10-10 |
US20060205733A1 (en) | 2006-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0514666A (pt) | antagonistas de receptor de endotelina a (eta) em combinação com inibidores de fosfodiestrase 5 (pdes) e usos destes | |
CY1121338T1 (el) | Χρηση αλατων του αναστολεα kinασης janus (r)-3-(4-(7h-πυρρολο[2,3-d]πυριμιδιν-4-υλο)-1η-πυραζολ-1-υλο)-3-κυκλοπεντυλο- προπανονιτριλιο | |
CY1122336T1 (el) | Eνωσεις πυρρολιου ως αναστολεις πρωτεϊνικων κινασων εrκ και φαρμακευτικες συνθεσεις που περιεχουν αυτες τις ενωσεις | |
DE602006004844D1 (de) | Pyrrolopyrimidine verwendbar als protein kinase inhibitoren | |
BR112013008140A2 (pt) | "compostos imidazotriazinona". | |
EA200602062A1 (ru) | Амидосоединения и их применение в качестве фармацевтических средств | |
BR112014030424A2 (pt) | formas cristalinas de um inibidor de quinase de tirosina de bruton | |
BR112014004504A2 (pt) | "composto como inibidor de c-kit cinase, seu uso, composição farmacêutica, e medicamento para o tratamento de uma doença mediada por uma cinase" | |
NO20071048L (no) | Amidoforbindelser og deres anvendelse som farmasoytika | |
NO20010743L (no) | Antivirale indoloksoacetyl-piperazin-derivater | |
WO2007087068A3 (en) | Inhibitors of tyrosine kinases and uses thereof | |
EA200701036A1 (ru) | Лактамные соединения и их применение в качестве фармацевтических препаратов | |
WO2006018024A3 (en) | Cosmetic and pharmaceutical compositions comprising ace inhibitors and/or angiotensin ii receptor antagonists | |
TW200604168A (en) | Azaindoles useful as inhibitors of rock and other protein kinases | |
ATE466580T1 (de) | Azolylaminoazine als proteinkinasehemmer | |
ATE468336T1 (de) | Azolylaminoazine als proteinkinasehemmer | |
ATE365733T1 (de) | Zusammensetzungen brauchbar als protein-kinase- inhibitoren | |
BRPI0518105A (pt) | uso de antagonista da angiogênese e uso de anticorpo anti-vegf | |
BRPI0512630A (pt) | compostos de amido e seu uso como produtos farmacêuticos | |
NO20053144L (no) | Chk-, Pdk- og Akt-inhibitorpyrimidiner, deres fremstilling og anvendelse som famasoytiske midler. | |
EA200700118A1 (ru) | Амидосоединения и их применение в качестве лекарственных средств | |
WO2006002361A3 (en) | 2-methylpropanamides and their use as pharmaceuticals | |
NO20072599L (no) | Inhibitorer av 11-beta-hydroksyl steroid dehydrogenase Type 1 og fremgangsmater for anvendelse derav | |
DE602007007985D1 (de) | Als inhibitoren von proteinkinasen geeignete aminopyrimidine | |
ATE435858T1 (de) | Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012. |